CaroGen
Business Services · Connecticut, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
400 Farmington Ave 2802, Farmington, Con...Phone Number
(203) 815-5782Website
www.carogencorp.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About CaroGen
CaroGen Corporation specializes in the development of immunotherapy and vaccine solutions, utilizing its innovative RNA-based AVIDIO platform for therapies targeting cancer and hepatitis B. The company is currently advancing two candidates, CARG-201 for chronic hepatitis B and CARG-2020 for ovarian cancer, which are in late-stage pre-clinical studies. Supported by significant funding from NIH and DoD, CaroGen aims to provide transformative treatments for patients worldwide. Their broad patent portfolio and ongoing clinical studies underscore their commitment to addressing critical health challenges in immuno-oncology.Explore more
CaroGen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CaroGen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if CaroGen has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once CaroGen has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
CaroGen, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if CaroGen had a recent Job posting/layoffs
Product Launch: Get notified when CaroGen launches new products
Check out if CaroGen is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on CaroGen recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at CaroGen
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to CaroGen
Compare insights from companies similar to CaroGen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CaroGen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CaroGen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CaroGen.
CaroGen financials insights
Gather financial insights about CaroGen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Angel/Seed
$150K
2016
Private Equity
$2.1M
CaroGen Tech Stack
A closer look at the technologies used by CaroGen
See more technologies
CaroGen News & Media
Prominent Immunologists Join CaroGen’s Scientific Advisory Board to...
Eminent new board members bring experience and deep expertise to Connecticut biotech company (PRWeb October 28, 2019) Read the full story at https://www.prweb.com/releases/prominent_immunologists_join_carogens_scientific_advisory_board_to_expand_and_expedite_immuno_oncology_pipeline/prweb16676442.htm
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CaroGen
Sign Up For FreeTo access detailed company insights
CaroGen Corporation specializes in the development of immunotherapy and vaccine solutions, utilizing its innovative RNA-based AVIDIO platform for therapies targeting cancer and hepatitis B. The company is currently advancing two candidates, CARG-201 for chronic hepatitis B and CARG-2020 for ovarian cancer, which are in late-stage pre-clinical studi... Read More
